Bianca Santonastaso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bianca Santonastaso has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Madelyn Gatchell
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY
2 shared publications- Majed A. Refaai
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY
2 shared publications Aimee Kievitt
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY
1 shared publicationAkua Asante
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY
1 shared publication- Benjamin L. Miller
Department of Biomedical Engineering, University of Rochester, Rochester, NY 14627, USA
1 shared publication - Christine Cahill
Mayo Clinic, Jacksonville, FL 32224, USA
1 shared publication
Latest Publications
- 5 May 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (5)
Prophylactic half-dose platelet transfusion effect on thrombocytopenia, transfusion, and bleeding occurrence in patients with hematologic disease
Objectives: To provide the lowest effective dose and minimize toxicity, our transfusion service initiated the use of a half-dose for all prophylactic inpatient platelet transfusions. The main rationale for this change in dose was the lack of evidence of increased bleeding and mortality in lower-dose platelet transfusion. Since the current platelet dose is not evidence based, and dose and toxicity are linked for most therapeutics, this approach to reducing adverse effects made scientific and clinical sense. In addition, many blood centers have experienced platelet shortages. Methods: This retrospective study included nonbleeding patients older than 50 years with a diagnosed hematologic disease who received prophylactic platelet transfusions and were admitted to our inpatient cancer center between November 1, 2023, and January 1, 2024. Results: Significantly lower volumes of platelets (153 vs 313 mL, P < .0001; 95% CI, 153-166) were administered to the study cohort (n = 310) vs the control (n = 301). No significant differences were seen in the number of transfusion events per hospitalization of platelets (4.4 vs 4.1, P = .7; 95% CI, –2.2 to 1.5) and red blood cells (5.9 vs 7.5, P = .29; 95% CI, –1.4 to 4.7). The mean platelet counts were similar between both groups in pretransfusion (10.3 vs 10 × 109/L, P = .73; 95% CI, –1.8 to 1.3) and posttransfusion (13.8 vs 15.9 × 109/L, P = .16; 95% CI, –0.88 to 5.1). Bleeding event frequency was also similar between both groups (1.6% vs 1.3%, respectively). Conclusions: Half-dose platelets appear to be safe and effective in nonbleeding patients receiving prophylactic transfusions. This strategy reduces patient exposure to potentially harmful higher-dose transfusions without increasing bleeding events or red blood cell transfusions.
- 5 May 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (5)
Prophylactic half-dose platelet transfusion effect on thrombocytopenia, transfusion, and bleeding occurrence in patients with hematologic disease
Objectives: To provide the lowest effective dose and minimize toxicity, our transfusion service initiated the use of a half-dose for all prophylactic inpatient platelet transfusions. The main rationale for this change in dose was the lack of evidence of increased bleeding and mortality in lower-dose platelet transfusion. Since the current platelet dose is not evidence based, and dose and toxicity are linked for most therapeutics, this approach to reducing adverse effects made scientific and clinical sense. In addition, many blood centers have experienced platelet shortages. Methods: This retrospective study included nonbleeding patients older than 50 years with a diagnosed hematologic disease who received prophylactic platelet transfusions and were admitted to our inpatient cancer center between November 1, 2023, and January 1, 2024. Results: Significantly lower volumes of platelets (153 vs 313 mL, P < .0001; 95% CI, 153-166) were administered to the study cohort (n = 310) vs the control (n = 301). No significant differences were seen in the number of transfusion events per hospitalization of platelets (4.4 vs 4.1, P = .7; 95% CI, –2.2 to 1.5) and red blood cells (5.9 vs 7.5, P = .29; 95% CI, –1.4 to 4.7). The mean platelet counts were similar between both groups in pretransfusion (10.3 vs 10 × 109/L, P = .73; 95% CI, –1.8 to 1.3) and posttransfusion (13.8 vs 15.9 × 109/L, P = .16; 95% CI, –0.88 to 5.1). Bleeding event frequency was also similar between both groups (1.6% vs 1.3%, respectively). Conclusions: Half-dose platelets appear to be safe and effective in nonbleeding patients receiving prophylactic transfusions. This strategy reduces patient exposure to potentially harmful higher-dose transfusions without increasing bleeding events or red blood cell transfusions.
- Open Access
Severe Bleeding Due to an Acquired FXIII Inhibitor in an Otherwise Healthy Patient
A 75-year-old male was admitted with worsening anemia and spontaneous bruising in the left abdominal wall and paraspinal region. Laboratory workup revealed low factor XIII (FXIII) activity levels. Cryoprecipitate transfusions raised his FXIII level, but still fluctuated drastically, ranging from 4 to 43% was discharged 3 days later once his bleeding was managed. Three days later, he was readmitted for severe pain and new bruising in his latissimus dorsi and lateral right thigh. CT-scan revealed hemothorax and arterial bleeding requiring an urgent angiogram with embolization. Chromogenic and functional FXIII assays were unable to elucidate an inhibitor at this time. Management included FXIII concentrate, rituximab, and prednisone; the patient was discharged 12 days later with FXIII levels of 50%. After prednisone tapering, FXIII levels decreased drastically. This case exemplified that higher levels of FXIII are required to prevent bleeding diatheses rather than the previously reported minimum of 5% activity. Despite the diagnostic uncertainty of laboratory testing, the shortened half-life of FXIII activity following replacement therapy and favorable response to immunotherapy indicates that the bleeding diathesis was caused by an acquired inhibitor.
Open AccessSevere Bleeding Due to an Acquired FXIII Inhibitor in an Otherwise Healthy Patient
A 75-year-old male was admitted with worsening anemia and spontaneous bruising in the left abdominal wall and paraspinal region. Laboratory workup revealed low factor XIII (FXIII) activity levels. Cryoprecipitate transfusions raised his FXIII level, but still fluctuated drastically, ranging from 4 to 43% was discharged 3 days later once his bleeding was managed. Three days later, he was readmitted for severe pain and new bruising in his latissimus dorsi and lateral right thigh. CT-scan revealed hemothorax and arterial bleeding requiring an urgent angiogram with embolization. Chromogenic and functional FXIII assays were unable to elucidate an inhibitor at this time. Management included FXIII concentrate, rituximab, and prednisone; the patient was discharged 12 days later with FXIII levels of 50%. After prednisone tapering, FXIII levels decreased drastically. This case exemplified that higher levels of FXIII are required to prevent bleeding diatheses rather than the previously reported minimum of 5% activity. Despite the diagnostic uncertainty of laboratory testing, the shortened half-life of FXIII activity following replacement therapy and favorable response to immunotherapy indicates that the bleeding diathesis was caused by an acquired inhibitor.
- Open Access
- 2 February 2026
- Published by Springer Nature in npj Biosensing
- Vol. 3 (1)
A multi-readout photonic sensor for rapid diagnosis of Von Willebrand disease
Von Willebrand Disease (VWD) is characterized by improper blood clotting, resulting from qualitative or quantitative changes in Von Willebrand factor (VWF). Diagnosis of VWD currently relies on measuring both the concentration of VWF and its activity by the binding ability to several different proteins, each of which are currently quantified separately. As such, the current diagnosis of VWD is complex and expensive, requiring multiple tests for a positive clinical determination. To address this challenge, we report a multiplexed biosensor that simultaneously measures VWF concentration and binding activity in plasma, enabling rapid diagnosis of VWD and discrimination among multiple subtypes. Using an 18-plex photonic ring resonator in a disposable, lateral flow assay-like format as the core technology, capture of VWF by an immobilized monoclonal antibody results in a red shift in resonance, which is referenced to a nonspecific binding control. Other ring resonators on the chip, functionalized with binding partners of VWF, allow simultaneous measurement of VWF binding to collagen, Factor VIII, and the GP1b receptor. Evaluation of a panel of 37 single-donor human plasma samples previously analyzed using FDA clinically approved assays demonstrated that the sensor has comparable concentration results and was able to accurately identify several categories of VWD (type 1, 2 A, and type 3).
- 2 February 2026
- Published by Springer Nature in npj Biosensing
- Vol. 3 (1)
Open AccessA multi-readout photonic sensor for rapid diagnosis of Von Willebrand disease
Von Willebrand Disease (VWD) is characterized by improper blood clotting, resulting from qualitative or quantitative changes in Von Willebrand factor (VWF). Diagnosis of VWD currently relies on measuring both the concentration of VWF and its activity by the binding ability to several different proteins, each of which are currently quantified separately. As such, the current diagnosis of VWD is complex and expensive, requiring multiple tests for a positive clinical determination. To address this challenge, we report a multiplexed biosensor that simultaneously measures VWF concentration and binding activity in plasma, enabling rapid diagnosis of VWD and discrimination among multiple subtypes. Using an 18-plex photonic ring resonator in a disposable, lateral flow assay-like format as the core technology, capture of VWF by an immobilized monoclonal antibody results in a red shift in resonance, which is referenced to a nonspecific binding control. Other ring resonators on the chip, functionalized with binding partners of VWF, allow simultaneous measurement of VWF binding to collagen, Factor VIII, and the GP1b receptor. Evaluation of a panel of 37 single-donor human plasma samples previously analyzed using FDA clinically approved assays demonstrated that the sensor has comparable concentration results and was able to accurately identify several categories of VWD (type 1, 2 A, and type 3).